Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix (ZGNX) on June 27 and set a price target of $58. The company’s shares closed on Friday at $47.78.
According to TipRanks.com, Yang is a 5-star analyst with an average return of 9.8% and a 44.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Alder Biopharmaceuticals, and Audentes Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zogenix with a $60.13 average price target, which is a 25.8% upside from current levels. In a report issued on June 27, Northland Securities also assigned a Buy rating to the stock with a $60 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $62.75 and a one-year low of $33.43. Currently, Zogenix has an average volume of 817.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
